A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

A clinical trial is now testing whether an experimental oral tablet, VX-993, can safely relieve the chronic nerve pain that afflicts roughly one in four people with long-term diabetes. Diabetic peripheral neuropathy (DPN) occurs when persistently high blood sugar damages small nerve fibres, typically in the feet and legs, causing burning, stabbing, or electric-shock-like pain. Existing treatments—such as gabapentinoids, antidepressants, or topical creams—often provide incomplete relief or cause intolerable side effects like dizziness and sedation. Many patients cycle through multiple drugs without finding one that works. This trial aims to fill that gap by testing a new chemical entity, VX-993, against an active comparator in a double-blind, dose-ranging design. If VX-993 proves effective and safe at a well-tolerated dose, it could become a new oral option for the hundreds of thousands of UK patients with DPN-related pain. That would directly improve quality of life for people who currently struggle with sleep, mobility, and daily activities due to unrelenting nerve pain. It would also give clinicians a fresh pharmacological tool for a condition where treatment options have not substantially expanded in years.